Literature DB >> 21762209

Therapeutic benefit of melatonin in experimental feline uveitis.

María José Del Sole1, Pablo H Sande, Diego C Fernandez, María Inés Keller Sarmiento, Marcelo A Aba, Ruth E Rosenstein.   

Abstract

Uveitis is a frequent ophthalmic disorder which constitutes one of the main causes of blindness in domestic cats. The aim of this report was to analyze the effect of melatonin on experimentally induced uveitis in cats. Bacterial lipopolysaccharide (LPS) was injected intravitreally into one eye from intact cats, while the contralateral eye was injected with vehicle. Melatonin was orally administered every 24 hr to a group of ten cats, from 24 hr before until 45 days after intravitreal injections. Eyes were evaluated by means of clinical evaluation, intraocular pressure (IOP), blood-ocular barrier integrity (via measurement of protein concentration and cell content in samples of aqueous humor [AH]), electroretinogram (ERG), and histological examination of the retinas. In LPS-treated eyes, several clinical signs were observed until day 45 postinjection. The treatment with melatonin significantly decreased clinical signs and prevented the reduction in IOP induced by LPS. In LPS-injected eyes, melatonin significantly preserved the blood-ocular barrier integrity, as shown by a decrease in the number of infiltrating cells and protein concentration in the AH. Mean amplitudes of scotopic ERG a- and b-waves were significantly reduced in eyes injected with LPS, whereas melatonin significantly prevented the effect of LPS. At 45 days after injection, LPS induced alterations in photoreceptors and at the middle portion of the retina, whereas melatonin preserved the retinal structure. These results indicate that melatonin prevented clinical, biochemical, functional, and histological alterations induced by LPS injection. Thus, melatonin might constitute a useful tool for the treatment of feline uveitis.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762209     DOI: 10.1111/j.1600-079X.2011.00913.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  6 in total

1.  Consecutive unilateral recording of the two eyes affects dark-adapted ERG responses, when compared to simultaneous bilateral recording.

Authors:  Maya Ross; Hen Honig; Raaya Ezra-Elia; Eyal Banin; Alexey Obolensky; Edward Averbukh; Alexander Rosov; Elisha Gootwine; Ron Ofri
Journal:  Doc Ophthalmol       Date:  2018-11-09       Impact factor: 2.379

2.  Treatment with melatonin after onset of experimental uveitis attenuates ocular inflammation.

Authors:  P H Sande; D Dorfman; D C Fernandez; M Chianelli; A P Domínguez Rubio; A M Franchi; D M Silberman; R E Rosenstein; D A Sáenz
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

3.  Critical Role of the CXCL10/C-X-C Chemokine Receptor 3 Axis in Promoting Leukocyte Recruitment and Neuronal Injury during Traumatic Optic Neuropathy Induced by Optic Nerve Crush.

Authors:  Yonju Ha; Hua Liu; Shuang Zhu; Panpan Yi; Wei Liu; Jared Nathanson; Rakez Kayed; Bradford Loucas; Jiaren Sun; Laura J Frishman; Massoud Motamedi; Wenbo Zhang
Journal:  Am J Pathol       Date:  2016-12-10       Impact factor: 4.307

Review 4.  Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases.

Authors:  Marcos L Aranda; María Florencia González Fleitas; Hernán Dieguez; Agustina Iaquinandi; Pablo H Sande; Damián Dorfman; Ruth E Rosenstein
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

5.  Melatonin Attenuates LPS-Induced Proinflammatory Cytokine Response and Lipogenesis in Human Meibomian Gland Epithelial Cells via MAPK/NF-κB Pathway.

Authors:  Ren Liu; Jing Li; Yue Xu; Ziyan Chen; Huijing Ye; Jinhui Tang; Lai Wei; Lingyi Liang
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-05-02       Impact factor: 4.925

6.  Dietary Melatonin Therapy Alleviates the Lamina Cribrosa Damages in Patients with Mild Cognitive Impairments: A Double-Blinded, Randomized Controlled Study.

Authors:  Lei Xu; Haixiang Yu; Hongbin Sun; Bang Hu; Yi Geng
Journal:  Med Sci Monit       Date:  2020-05-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.